ZyVersa Therapeutics (NASDAQ:ZVSA) Trading Up 7.5%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA)’s share price was up 7.5% during trading on Thursday . The stock traded as high as $0.64 and last traded at $0.63. Approximately 422,022 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 2,335,399 shares. The stock had previously closed at $0.58.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of ZyVersa Therapeutics in a research note on Tuesday, March 26th.

ZyVersa Therapeutics Trading Down 6.4 %

The firm has a 50-day simple moving average of $0.76 and a 200-day simple moving average of $1.63.

Institutional Investors Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Walleye Capital LLC bought a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned approximately 3.17% of ZyVersa Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 3.91% of the company’s stock.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.